We previously demonstrated the use of near-infrared (NIR) imaging to evaluate differences in disintegration for various capsule formulations after oral administration to rats. To further explore this techniques utility, in vitro and in vivo studies were conducted using mini tablets (2.5 mm in diameter and 2.17 mm in thickness) containing indocyanine green (ICG), acetaminophen (ACE), metoprolol tartrate (MET), and atenolol (ATE), prepared and coated with two different thicknesses of Eudragit® L 30 D-55. The in vitro results showed that the coated mini tablets exhibited acid resistance with slow leakage in acidic media and rapid release with a short lag time under neutral pH conditions as a function of coating thickness. Consistent with the in vitro dissolution profiles, oral drug absorption was also substantially affected by coating thickness. Although the AUC of ACE decreased only slightly, Cmax decreased significantly, and Tmax was prolonged with coating thickness increase. Similar trends in Cmax and Tmax were observed for MET and ATE; however, their AUCs decreased markedly with increasing coating thickness. ICG fluorescence intensity and area time profiles, which reflect the amount and extent of drug dissolved in the intestine, closely corresponded to the absorption profile of ACE quantified by deconvolution analysis, further suggesting distinct MET and ATE absorption characteristics. Collectively, these findings demonstrate that NIR imaging is a valuable tool for evaluating in vivo drug release from coated mini tablets.
Introduction
Oral drug absorption is influenced by dissolved concentration in gastrointestinal (GI) fluids, intestinal epithelium permeability, and effective transit time. Drug concentration and effective transit time in the GI tract are influenced by formulation design, allowing for the design of different plasma profiles. Sustained- and controlled-release formulations regulate drug absorption profiles according to their release characteristics. Sustained-release (SR) formulations enable continuous drug delivery to the intestine, thereby reducing absorption rate, suppressing rapid increases in plasma drug concentration, and maintaining stable plasma levels. Additionally, the use of hydrophilic matrix systems and pH-dependent polymers in SR formulations enables greater control over drug availability. To develop effective formulation strategies targeting distal intestinal regions, such as the large intestine, accurate prediction of in vivo drug-release profiles in humans is crucial [[1], [2], [3], [4], [5]].
Several methodologies to assess in vivo drug release profiles are known. Radioactive compounds constitute one such non-invasive method for evaluating in vivo drug-release profiles in humans [[6], [7], [8], [9], [10]]. Although yielding valuable information such as GI transit and formulation disintegration, this approach requires dosage forms that incorporate potentially problematic radioactive compounds. Furthermore, the relationship between plasma drug profiles and these in vivo imaging approaches is not fully elucidated. We recently reported the application of near-infrared (NIR) imaging to evaluate the in vivo performance of orally administered formulations in rats by exploiting the physicochemical property that dissolution increases NIR intensity [11]. Differences in disintegration rates between gelatin and hydroxypropyl methylcellulose capsules containing indocyanine green (ICG) as an NIR imaging agent were clearly demonstrated in rats, suggesting that NIR imaging may be a useful tool to evaluate in vivo release profiles.
In this study, the relationship between drug release from SR formulations and oral absorption was investigated through comparison of NIR fluorescence imaging with plasma drug concentrations. Mini tablets with a polymer coating were prepared as a model SR formulation. Three types of mini tablets, each containing ICG, a NIR probe, together with model drugs, acetaminophen (ACE), atenolol (ATE), and metoprolol tartrate (MET), were coated using different thicknesses of Eudragit® L 30 D-55. The tablets were characterized by in vitro dissolution testing. Oral administration studies combined with NIR imaging and blood sampling were conducted in fasted rats. Finally, correlations between parameters obtained from plasma drug concentration profiles and NIR image analyses were evaluated.
Materials
ACE, ATE, and MET were purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). ICG (DIAGNOGREEN® FOR INJECTION) was purchased from Daiichisankyo Co., Ltd. (Tokyo, Japan). Lactose (
Super Tab 11SD),
cornstarch (Nihon Shokuhin Kako Co., Ltd., Tokyo, Japan), hydroxypropyl cellulose (
HPC-L), and magnesium stearate were obtained from
DFE Pharma (Goch, Germany), Nihon Shokuhin Kako Co., Ltd. (Tokyo, Japan),
Asahi Kasei Corp. (Tokyo, Japan), and Taihei Chemical Industrial Co., Ltd.
Makoto Kataoka, Nanami Matsuura, Takato Masada, Keiko Minami, Haruki Higashino, Takuya Nagato, Shinji Yamashita,
Simultaneous evaluation of drug absorption and in vivo release behavior from coated mini tablets with Eudragit L 30 D-55 in rats using near-infrared imaging,
Journal of Drug Delivery Science and Technology,
Volume 117, 2026, 107996, ISSN 1773-2247,
https://doi.org/10.1016/j.jddst.2026.107996.
(https://www.sciencedirect.com/science/article/pii/S1773224726000213)